⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington’s Disease (P6-3.009)

Shuhei Shiino Daniel Kim Paul R. Slaughter Katie Hay Claudia Raines Christina Durrough Kristina Vaughn Michael de Riesthal Antje S. Mefferd Amy Frances Brown

View Full Paper

Ask AI

Bookmark

Share

Abstract

To examine the effect of deutetrabenazine on functional speech production and gait dynamics in individuals with Huntington's Disease (HD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shiino et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db6435876773c6 https://doi.org/10.1212/wnl.0000000000205788

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease2024 · 4 citations
2Huntington Disease Treated with Austedo (Deutetrabenazine)2024 · 1 citations
3Real-world Use of Deutetrabenazine Reduces Tardive Dyskinesia Severity and Improves Quality of Life: Patient-reported Outcomes in the IMPACT-TD Study (P7-16.004)other · 2026
4Effectiveness and Satisfaction with Deutetrabenazine in Huntington Disease When Initiated Using a 4-week Patient Titration Kit: Final Results of the START Study (P8-3.008)2024
5Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review studyCohort Study · 2026